|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Oct 3, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Assets | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Accounts Receivables – related parties | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Total accounts Receivables – related parties | ||||||||||||||||||||
| Other receivables – related parties | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Total other receivables – related parties | ||||||||||||||||||||
| Other current assets | ||||||||||||||||||||
| Investment in unconsolidated entities held for sale (Note 3b) | ||||||||||||||||||||
| Other receivables | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Total other receivables | ||||||||||||||||||||
| Related parties receivables | ||||||||||||||||||||
| Total Current Assets | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Investment in unconsolidated entity | ||||||||||||||||||||
| Intangible assets | ||||||||||||||||||||
| Total Non-Current Assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Current Liabilities | ||||||||||||||||||||
| Short term credit | ||||||||||||||||||||
| Trade payable | ||||||||||||||||||||
| Other accounts liabilities | ||||||||||||||||||||
| Liability to an unconsolidated entity (Note 1) | ||||||||||||||||||||
| Liability to an unconsolidated entity | ||||||||||||||||||||
| Liabilities to an unconsolidated entity | ||||||||||||||||||||
| Warrants liability, net | ||||||||||||||||||||
| Deferred revenue | ||||||||||||||||||||
| Notes and Loan payable | ||||||||||||||||||||
| Total Current Liabilities | ||||||||||||||||||||
| Other long-term loans | ||||||||||||||||||||
| Total Non-Current Liabilities | ||||||||||||||||||||
| Long Term Liabilities | ||||||||||||||||||||
| Investment in unconsolidated entity | ||||||||||||||||||||
| Total Liabilities | ||||||||||||||||||||
| Stockholders’ Deficit | ||||||||||||||||||||
| Common stock, 0.001 par value each: 27,692,308 shares authorized as of June 30, 2026 and December 31, 2025, respectively; issued and outstanding 7,942,407 shares as of June 30, 2026 and 4,377,388 as of December 31, 2025. | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Treasury Stock | ||||||||||||||||||||
| Receipts on account of shares | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total Stockholders’ Deficit | ||||||||||||||||||||
| Total Liabilities and Stockholders’ Deficit | ||||||||||||||||||||
Loading...
